Haythem Y. Ali

An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.

M. Kreissl, M. Schlumberger, P. Schőffski, 2012 .

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

M. Kreissl, M. Schlumberger, M. Brose, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.